ATE252902T1 - Verwendung von calciumkanalanantagonisten zur behandlung von herz-, nieren-, magen-und darmkrankheiten sowie bluthochdruck - Google Patents

Verwendung von calciumkanalanantagonisten zur behandlung von herz-, nieren-, magen-und darmkrankheiten sowie bluthochdruck

Info

Publication number: ATE252902T1
Authority: AT; Austria
Prior art keywords: hypertension; stomach; kidney; heart; treatment
Prior art date: 1995-06-07

Application number

AT96918210T

Other languages

English (en)

Inventor

Marlene L Cohen

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-04

Publication date

2003-11-15

1996-06-04 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2003-11-15 Application granted granted Critical

2003-11-15 Publication of ATE252902T1 publication Critical patent/ATE252902T1/de

Links

229940127291 Calcium channel antagonist Drugs 0.000 title 1
206010020772 Hypertension Diseases 0.000 title 1
210000002216 heart Anatomy 0.000 title 1
208000019622 heart disease Diseases 0.000 title 1
208000028774 intestinal disease Diseases 0.000 title 1
210000003734 kidney Anatomy 0.000 title 1
208000017169 kidney disease Diseases 0.000 title 1
210000002784 stomach Anatomy 0.000 title 1
208000018556 stomach disease Diseases 0.000 title 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
108090000312 Calcium Channels Proteins 0.000 abstract 1
102000003922 Calcium Channels Human genes 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
-1 hexamethylenemino Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

AT96918210T 1995-06-07 1996-06-04 Verwendung von calciumkanalanantagonisten zur behandlung von herz-, nieren-, magen-und darmkrankheiten sowie bluthochdruck ATE252902T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/485,406 US5840747A (en)	1995-06-07	1995-06-07	Calcium channel antagonists
PCT/US1996/009162 WO1996040134A1 (en)	1995-06-07	1996-06-04	Calcium channel antagonists

Publications (1)

Publication Number	Publication Date
ATE252902T1 true ATE252902T1 (de)	2003-11-15

Family

ID=23928032

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96918210T ATE252902T1 (de)	1995-06-07	1996-06-04	Verwendung von calciumkanalanantagonisten zur behandlung von herz-, nieren-, magen-und darmkrankheiten sowie bluthochdruck

Country Status (21)

Country	Link
US (1)	US5840747A (de)
EP (1)	EP0831822B1 (de)
JP (1)	JPH11506788A (de)
KR (1)	KR19990022499A (de)
CN (1)	CN1193274A (de)
AT (1)	ATE252902T1 (de)
AU (1)	AU714403B2 (de)
CA (1)	CA2223711A1 (de)
CZ (1)	CZ288546B6 (de)
DE (1)	DE69630523T2 (de)
EA (1)	EA001928B1 (de)
ES (1)	ES2210373T3 (de)
HU (1)	HUP9900916A3 (de)
IL (1)	IL122459A (de)
MX (1)	MX9709468A (de)
NO (1)	NO975561L (de)
NZ (1)	NZ310178A (de)
PL (1)	PL183998B1 (de)
RO (1)	RO116344B1 (de)
UA (1)	UA43895C2 (de)
WO (1)	WO1996040134A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6008232A (en) *	1997-08-20	1999-12-28	Eli Lilly And Company	Methods for preventing headaches
AU7896100A (en) *	1999-10-14	2001-04-23	Endorecherche Inc.	Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
EP1113007A1 (de)	1999-12-24	2001-07-04	Pfizer Inc.	Tetrahydroisochinolin-Verbindungen zur Verwendung als Östrogen-Agonisten/-Antagonisten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4133814A (en) *	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
US5441965A (en) *	1993-12-21	1995-08-15	Eli Lilly And Company	Methods of inhibiting thrombin
US5447941A (en) *	1993-12-21	1995-09-05	Eli Lilly And Company	Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US6562862B1 (en) *	1994-10-20	2003-05-13	Eli Lilly And Company	Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5532254A (en) *	1995-06-07	1996-07-02	Eli Lilly And Company	Modulation of calcium channels using benzothiophenes

1995
- 1995-06-07 US US08/485,406 patent/US5840747A/en not_active Expired - Fee Related
1996
- 1996-04-06 UA UA97125831A patent/UA43895C2/uk unknown
- 1996-06-04 NZ NZ310178A patent/NZ310178A/en unknown
- 1996-06-04 AU AU60919/96A patent/AU714403B2/en not_active Ceased
- 1996-06-04 WO PCT/US1996/009162 patent/WO1996040134A1/en not_active Ceased
- 1996-06-04 EA EA199800033A patent/EA001928B1/ru not_active IP Right Cessation
- 1996-06-04 ES ES96918210T patent/ES2210373T3/es not_active Expired - Lifetime
- 1996-06-04 EP EP96918210A patent/EP0831822B1/de not_active Expired - Lifetime
- 1996-06-04 MX MX9709468A patent/MX9709468A/es not_active IP Right Cessation
- 1996-06-04 RO RO97-02247A patent/RO116344B1/ro unknown
- 1996-06-04 HU HU9900916A patent/HUP9900916A3/hu unknown
- 1996-06-04 AT AT96918210T patent/ATE252902T1/de not_active IP Right Cessation
- 1996-06-04 PL PL96324086A patent/PL183998B1/pl unknown
- 1996-06-04 CN CN96195976A patent/CN1193274A/zh active Pending
- 1996-06-04 KR KR1019970708980A patent/KR19990022499A/ko not_active Ceased
- 1996-06-04 CA CA002223711A patent/CA2223711A1/en not_active Abandoned
- 1996-06-04 DE DE69630523T patent/DE69630523T2/de not_active Expired - Fee Related
- 1996-06-04 JP JP9501551A patent/JPH11506788A/ja active Pending
- 1996-06-04 CZ CZ19973828A patent/CZ288546B6/cs not_active IP Right Cessation
- 1996-06-04 IL IL12245996A patent/IL122459A/en not_active IP Right Cessation
1997
- 1997-12-02 NO NO975561A patent/NO975561L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL324086A1 (en)	1998-05-11
CZ382897A3 (cs)	1999-01-13
EA001928B1 (ru)	2001-10-22
ES2210373T3 (es)	2004-07-01
EP0831822B1 (de)	2003-10-29
DE69630523T2 (de)	2004-08-12
AU6091996A (en)	1996-12-30
IL122459A0 (en)	1998-06-15
KR19990022499A (ko)	1999-03-25
NZ310178A (en)	2000-06-23
MX9709468A (es)	1998-04-30
EP0831822A4 (de)	2001-12-19
NO975561D0 (no)	1997-12-02
EP0831822A1 (de)	1998-04-01
UA43895C2 (uk)	2002-01-15
JPH11506788A (ja)	1999-06-15
CZ288546B6 (cs)	2001-07-11
CA2223711A1 (en)	1996-12-19
US5840747A (en)	1998-11-24
WO1996040134A1 (en)	1996-12-19
CN1193274A (zh)	1998-09-16
EA199800033A1 (ru)	1998-06-25
HUP9900916A2 (hu)	1999-09-28
NO975561L (no)	1997-12-02
DE69630523D1 (de)	2003-12-04
IL122459A (en)	2001-05-20
HUP9900916A3 (en)	1999-11-29
AU714403B2 (en)	2000-01-06
RO116344B1 (ro)	2001-01-30
PL183998B1 (pl)	2002-08-30

Legal Events

Date	Code	Title	Description
2004-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69625691D1 (de)	2003-02-13	Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69507029D1 (de)	1999-02-11	Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
DK0664126T3 (da)	1997-09-01	Hæmning af trombin
UA43391C2 (uk)	2001-12-17	Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію
ATE189601T1 (de)	2000-02-15	Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
RU94044454A (ru)	1996-10-10	Ингибитор аутоимунных заболеваний
EA199800019A1 (ru)	1998-06-25	Способ повышения плотности кальциевых каналов
DE60130030D1 (de)	2007-09-27	Verfahren zur behandlung von glaukom
SE9403831D0 (sv)	1994-11-08	A storage stable water solution for infusion I
EA199700136A1 (ru)	1997-12-30	Способы ингибирования экзогенных эстрогенов
DE69630523D1 (de)	2003-12-04	Verwendung von Calciumkanalanantagonisten zur Behandlung von Herz-, Nieren-, Magen-und Darmkrankheiten sowie Bluthochdruck
DK0659414T3 (da)	2001-09-24	Inhibering af hirutisme og alopeci hos kvinder
DE69926357D1 (de)	2005-09-01	Vorbereitung eines medikaments zur behandlung von refluxösophagitis
DK0769945T3 (da)	2003-06-10	Brug af 2-phenyl-3-aroylbenzothiophenderivater til fremstilling af et medikament til behandling af knogler og knoglebrud
ATE207353T1 (de)	2001-11-15	Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
ATE212842T1 (de)	2002-02-15	Quinoxalin-derivate zur behandlung von tinnitus
DE69509657D1 (de)	1999-06-17	Verwendung von benzothiophenen zur herstellung eines medikaments zur verminderung der narbenbildung bei der wundheilung
ATE81465T1 (de)	1992-10-15	Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.